These findings suggest that genetic liabilities to critically ill COVID-19 increased the risk of HER2-positive breast cancer by activating IgD- CD27- AC and CD27 on IgD + CD38- unsw mem (Fig. 5). This evidence concerns the gene ERBB2 and breast carcinoma.